Kyverna Therapeutics, Inc. (KYTX) — Financial statements
Income statement, balance sheet, and cash flow for Kyverna Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00↓100.0% | 7↑24.2% | 6 | |
| Cost of Revenue | 0.00↓100.0% | 2↑25.0% | 2 | 0.00 | 0.00 | |
| Gross Profit | 0.00↑100.0% | -2↓25.0% | -2↓124.3% | 7↑24.2% | 6 | |
| Operating Expenses | ||||||
| R&D Expenses | 134↑18.9% | 112↑133.3% | 48↑69.8% | 28↑9.9% | 26 | |
| General & Administrative Expenses | 36↑19.8% | 30 | 0.00↓100.0% | 8↑30.2% | 6 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 36↑19.8% | 30↑141.4% | 12↑55.9% | 8↑30.2% | 6 | |
| Other Expenses | 0.00↑100.0% | -2 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 170↑20.9% | 140↑131.4% | 61↑66.7% | 36↑13.8% | 32 | |
| Total Costs & Expenses | 170↑19.1% | 143↑128.5% | 62↑71.4% | 36↑13.8% | 32 | |
| Operating Results | ||||||
| Operating Income | -170↓19.1% | -143↓128.5% | -62↓112.4% | -29↓11.5% | -26 | |
| Depreciation & Amortization | 2↓15.7% | 2↑25.0% | 2↑62.4% | 1↑79.4% | 0.59 | |
| EBITDA | -159↓27.0% | -125↓114.1% | -58↓110.5% | -28↓7.8% | -26 | |
| EBIT | -161↓26.3% | -127↓111.6% | -60↓108.8% | -29↓9.4% | -26 | |
| Interest & Other Income | ||||||
| Net Interest Income | 9↓43.5% | 15↑626.3% | 2↑319.0% | 0.50↑25100.0% | -0.00 | |
| Interest Income | 9↓40.8% | 15↑573.0% | 2↑303.9% | 0.57↑56400.0% | 0.00 | |
| Interest Expense | 0.49↑244.4% | 0.14↓24.1% | 0.19↑187.7% | 0.07↑2066.7% | 0.00 | |
| Non-Operating Income | -9↑41.0% | -15↓585.6% | -2↓300.5% | -0.56↓55700.0% | 0.00 | |
| Other Income / Expenses | 9↓43.7% | 15↑641.5% | 2↑315.5% | 0.49↑12375.0% | -0.00 | |
| Income Before Tax | -161↓26.5% | -127↓111.2% | -60↓108.9% | -29↓9.7% | -26 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -161↓26.5% | -127↓111.2% | -60↓108.9% | -29↓9.7% | -26 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -161↓26.5% | -127↓111.2% | -60↓108.9% | -29↓9.7% | -26 | |
| Bottom-Line Net Income | -161↓26.5% | -127↓111.2% | -60↓108.9% | -29↓9.7% | -26 | |
| EPS (Basic) | -3.64↓9.3% | -3.33↓3329900.0% | -0.00↑100.0% | -1.12↓9.8% | -1.02 | |
| EPS (Diluted) | -3.64↓9.3% | -3.33↓3329900.0% | -0.00↑100.0% | -1.12↓9.8% | -1.02 | |
| Weighted Average Shares | 44↑15.5% | 38↓94.3% | 674↑2510.5% | 26↑0.0% | 26 | |
| Weighted Average Diluted Shares | 44↑15.5% | 38↓94.3% | 674↑2510.5% | 26↑0.0% | 26 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.